Copley Scientific to launch new low capacity pump for inhaler testing at DDL 19

In response to customer demand, Copley Scientific is launching a new pump for inhaler testing at low flow rates. The Low Capacity Pump LCP5 will make its debut at Drug Delivery to the Lungs (DDL) 19 to be held in Edinburgh, UK, from 10 to 12 December 2008.

All inhaled drug products are tested using the in-vitro technique of cascade impaction, which determines the aerodynamic particle size distribution of the aerosol produced. Generating the appropriate air flow rate through the impactor during testing is an important performance factor.

The LCP5 is a small footprint, sound insulated, low vibration vacuum pump designed for optimal operation at low flow rates. This makes it ideal for nasal sprays and metered dose inhalers (MDIs) which are tested at 28.3 (or 30) L/min, and nebulisers which are typically tested at 15 L/min. The pump, which includes an in-built variable flow control valve and the required hose fittings, is suitable for use with all USP and Ph.Eur. specified impactors. This includes both the Andersen Cascade Impactor (ACI) and Next Generation Pharmaceutical Impactor (NGI). Copley also offers a well-established high capacity pump for the higher, sonic flow rate testing requirements of dry powder inhalers (DPIs).

Experts from the company will be on hand throughout DDL to provide advice and discuss the full range of products. Copley Scientific’s commitment to the inhaler development community is further underlined by its sponsorship of the European Pharmaceutical Aerosol Group (EPAG) plenary and impactor sub-group meetings, to be held in Edinburgh prior to DDL.

DDL (Drug Delivery to the Lungs) is the premier European conference relating to the development of inhalers for the treatment of respiratory illness and the delivery of systemic therapeutics.